CSF Markers of Neuronal Injury Drop When Dementia Arrives
What goes up can come down—rising tides of VILIP-1, neurogranin, and SNAP-25 ebb after onset of AD symptoms.
ALL NEWS
612 RESULTS
Sort By:
- Most Recent
- Most Commented
Parental Age of Onset Helps Predict Amyloid Accumulation in Sporadic AD, Too
In three independent cohorts, cognitively healthy people had a higher amyloid burden as they approached the age at which their parents developed late-onset AD.
Aβ, Then Metabolism, Then Atrophy: In Familial AD, Cascade is Definitive
Longitudinal neuroimaging of DIAN participants reveals that in most regions of the brain affected by AD pathology, Aβ accumulates first, then metabolism slows, then the brain shrinks.
In Familial Alzheimer’s, Tau Creeps into Cortex as Symptoms Show
In people with an autosomal-dominant AD mutation, Aβ and tau start accumulating long before the estimated onset of symptoms.
Closing in on a Blood Test for Alzheimer’s?
A Japanese company enters the arena with a plasma Aβ test that rivals CSF for detecting brain amyloid.
It’s Official: CSF Aβ42 Reference Standard Will Unify Assays
Certified reference material by which companies can calibrate assays is now available worldwide.
Aβ, Tau Absolved of Causing Mild Cognitive Impairment in Parkinson’s
PET scans indicate no more AD pathology in PD-MCI than healthy controls, suggesting their cognitive decline results from other factors.
Before 40, Brain Atrophy in ALS Mutation Carriers?
In people who carry a repeat expansion in the C9ORF72 gene, gray and white matter are smaller and subtle impairments in cognition appear decades before symptom onset.
Automated CSF Tests: Check. Blood Tests: In the Works
Clinical validation is showing automated Elecsys, Lumipulse assays to be reliable and predictive. The story on blood tests has turned from non-starter to intensely promising for broad-based screening.
At CTAD, Tau PET Emerges as Favored Outcome Biomarker for Trials
Tau’s apparent lockstep with cognitive decline dominated the PET conversation. Piramal flaunted data, and Merck/Cerveau are close behind. A first stab at imaging synapses in the hippocampus drew notice, too.
10th CTAD: Finally, Alzheimer’s Field Is Serious About Prevention Trials
Alzheimer’s science has undergone a paradigm shift toward the disease’s silent phase. For trials, this means change at every level: new participants, new screening tools, new outcome measurements. What’s the progress?
In ALS, Respiratory Measure Predicts Pace of Disease
Slow vital capacity, a measure of respiratory function, predicted the rate of disease progression in ALS patients, suggesting the test could be used as a primary endpoint in clinical trials.
Serum NfL Detects Preclinical AD, Reflects Clinical Benefit
The neurodegeneration marker appears to track disease severity in AD and MS patients with great sensitivity.
Daydreaming Network Serves as Ground Zero for Aβ Deposition
A longitudinal study identified regions in the default mode network as among the first to accumulate Aβ.
Among the Healthy, a Positive Amyloid Scan Prompts Questions About Risk
Participants in the A4 prevention trial wanted to know the extent of their amyloid burdens and how that affected their risk for AD. Researchers need to carefully communicate the limitations of amyloid PET.
Current Filters
- Biomarkers x